Biofrontera Inc.(BFRI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,478 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
BFRI Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Biofrontera Inc. (BFRI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BFRI at 30.9/100 on a 32-signal composite quality model, placing it at rank #2,478 of 2,962 stocks — the bottom half of the AI-ranked universe. BFRI scores in the top quartile across revenue growth (83.0). Areas of concern include earnings quality (6.5) and balance sheet strength (8.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Biofrontera Inc. reports quarterly revenue of $12.0M, net income of $-604.0K, free cash flow of $-1.7M. Top institutional holders of BFRI by reported 13-F value include Rosalind Advisors, AIGH Capital Management, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. BFRI trades on the Nasdaq exchange and files with the SEC under CIK 1858685. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BFRI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Biofrontera Inc. directly from SEC EDGAR. Biofrontera Inc.'s 13F Pro composite quality score has ranged between 10 and 32 since 2023, currently 30.9 — an improving long-term trajectory across 61 quarterly and live scoring snapshots.
Revenue
Q2 2026
$12.0M
Net Income
Q2 2026
$-604.0K
Free Cash Flow
Q2 2026
$-1.7M
ROIC
Q2 2026
-35.2%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+11.7% YoYNet Income
+40.7% YoYOperating Income
+34.1% YoYEPS (Diluted)
+67.7% YoYTotal Assets
+29.2% YoYTotal Debt
Op. Cash Flow
-30.1% YoYFree Cash Flow
-30.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $41.7M +11.7% | $37.3M +9.5% | $34.1M +18.8% | $28.7M +19.0% | $24.1M +27.9% | $18.8M |
| Net Income | $-10.5M +40.7% | $-17.8M +11.8% | $-20.1M -3045.5% | $-640.0K +98.3% | $-37.7M -243.3% | $-11.0M |
| Operating Income | $-11.3M +34.1% | $-17.2M +24.1% | $-22.7M -22.0% | $-18.6M +26.3% | $-25.2M -162.3% | $-9.6M |
| EPS (Diluted) | $-1.04 +67.7% | $-3.22 +75.3% | $-13.02 -2034.4% | $-0.61 | — | — |
| Total Assets | $28.6M +29.2% | $22.1M -20.9% | $27.9M -45.1% | $50.9M -4.4% | $53.2M +120.5% | $24.1M |
| Total Debt | — | — | $3.9M | — | — | — |
| Operating Cash Flow | $-13.4M -30.1% | $-10.3M +58.7% | $-24.9M -53.7% | $-16.2M +39.4% | $-26.7M -116.0% | $-12.4M |
| Free Cash Flow | $-13.4M -30.0% | $-10.3M +58.7% | $-24.9M -53.4% | $-16.2M | — | — |
Get alerted when BFRI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Biofrontera Inc. including:
Top Institutional Holders of BFRI
Rosalind Advisors, Inc.
$1.2M1,275,609 shAIGH Capital Management LLC
$699.6K739,910 shRENAISSANCE TECHNOLOGIES LLC
$148.9K157,505 shCITADEL ADVISORS LLC
$99.2K104,941 shJANE STREET GROUP, LLC
$87.9K93,000 shGEODE CAPITAL MANAGEMENT, LLC
$72.5K76,689 shVANGUARD CAPITAL MANAGEMENT LLC
$67.5K71,380 shVANGUARD FIDUCIARY TRUST CO
$58.4K61,697 shXTX Topco Ltd
$49.1K51,894 shHRT FINANCIAL LP
$40.0K43,349 sh
| Fund | Value | Shares |
|---|---|---|
| Rosalind Advisors, Inc. | $1.2M | 1,275,609 |
| AIGH Capital Management LLC | $699.6K | 739,910 |
| RENAISSANCE TECHNOLOGIES LLC | $148.9K | 157,505 |
| CITADEL ADVISORS LLC | $99.2K | 104,941 |
| JANE STREET GROUP, LLC | $87.9K | 93,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $72.5K | 76,689 |
| VANGUARD CAPITAL MANAGEMENT LLC | $67.5K | 71,380 |
| VANGUARD FIDUCIARY TRUST CO | $58.4K | 61,697 |
| XTX Topco Ltd | $49.1K | 51,894 |
| HRT FINANCIAL LP | $40.0K | 43,349 |
Companies Similar to BFRI
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
FENNEC PHARMACEUTICALS INC.
Apyx Medical Corp
ORTHOPEDIATRICS CORP
Ovid Therapeutics Inc.
Verastem, Inc.
X4 Pharmaceuticals, Inc
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put BFRI on your watchlist
Track score changes the day Biofrontera Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BFRI a good stock to buy?
13F Pro's AI-powered analysis of Biofrontera Inc. (BFRI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BFRI are available on the BFRI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BFRI is classified as a small company.
Which hedge funds own BFRI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BFRI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Biofrontera Inc.'s investment landscape.